Mindera Corporation Raises $5.3M Series A to Commercialize Psoriasis Biologic Responsiveness Test

SAN DIEGO, CA –  Mindera Corporation has announced that it closed a $5.3M Series A financing on November 14, 2019 led by Mountain Group Partners and Scientific Health Development.  The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as to continue development of the Mindera Dermal Intelligence™ Platform.

The company also announced that Joe Cook, III of Mountain Group Partners was elected to the Mindera Board of Directors.

“We are very excited to be helping Mindera develop and commercially launch Mind.Px.  By non-invasively accessing site specific biomarkers, Mind.Px generates information that can help to truly bring about personalized medicine to patients and their providers in dermatology,” said Joe Cook, III.

Mindera has a developed a novel platform to extract thousands of biomarkers (RNA, DNA, proteins) from an individual patient via a dermal biomarker patch. Captured RNA is then sent to a CLIA lab for Next-Generation Sequencing (NGS). Using Machine Learning, these biomarkers are correlated to clinical outcomes data from myriad psoriasis patients who receive specific biologic drugs, resulting in predictive analyses for personalized drug responses. Systemwide, predicting biologic responses through Mind.Px can result in both improved patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.

About Mindera:

Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level.  Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes.  Find out more at www.minderadx.com.